Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.
Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.
Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.
Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.